{
    "nctId": "NCT02571894",
    "briefTitle": "The Cardio-Oncology Breast Cancer Study",
    "officialTitle": "Effects of Identifying and Treating Early, Subclinical Cardiotoxicity on the Long-Term Incidence of Clinical Cardiotoxicity in Women With Breast Cancer, A Prospective Randomized Study: The Cardio-Oncology Breast Cancer Study (COBC)",
    "overallStatus": "UNKNOWN",
    "conditions": "Cardiotoxicity, Cardiomyopathies, Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 320,
    "primaryOutcomeMeasure": "Event free survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women with newly diagnosed breast cancer who are eligible to receive neo-adjuvant or adjuvant chemotherapy, with or without trastuzumab, according to the guidelines for breast cancer.\n* Written informed consent must be given.\n\nExclusion Criteria:\n\n* A history of heart disease; ischemic heart disease, arrhythmias, heart failure, and valve diseases.\n* Previously received oncological treatment for any malignancy.\n* Other disease or conditions that complicates or precludes the patient from following the study protocol.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}